Prader Willi Syndrome (BSN175)

Prader Willi syndrome (PWS) is a pediatric rare disease that leads to life-threatening
obesity in children. PWS results from an abnormality on chromosome 15. It occurs in males and females equally and in all races.  BSN175 is an FDA-designated orphan compound for the treatment of Prader Willi syndrome.  BSN175 is in phase 3 clinical trials.

 

ADHD in Fragile X Syndrome (BSN608)

Attention Deficit Hyperactivity Disorder (ADHD) is a significant problem in patients with Fragile X Syndrome (FXS), a pediatric rare disease. BSN608 is the drug portion of a combined drug/device therapy for ADHD in FXS.  The device portion of the therapy is a video game in which 10 different virtual worlds are used to treat specific executive function deficits in patients with ADHD and FXS.  A clinical trial is currently underway to test the efficacy of the combination therapy.

 

Ebola (BSN389)

Ebola virus disease is a deadly tropical disease with occasional outbreaks that occur primarily on the African continent. The disease most commonly affects people and nonhuman primates (e.g., monkeys, gorillas, and chimpanzees). BSN389 is an antiviral FDA-designated orphan compound for the treatment of Ebola virus infections.  While human data exist from phase 1 clinical trials, BSN389 is being processed by FDA under the Animal Rule

 

COVID-19 (BSN389)

Coronavirus (COVID-19) is a pandemic illness caused by a virus that can spread easily from person to person. BSN389 is an antiviral for Ebola that may also work against COVID-19.

 

Chikungunya (BSN476)

Chikungunya virus is a tropical disease spread to humans by the bite of an infected mosquito. The most common symptoms of infection are fever and joint pain, which can become permanent. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean.  BSN476 is an antiviral compound used to inhibit replication of chikungunya virus.